For research use only. Not for therapeutic Use.
DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases[1].
DAPK-IN-2 (10 μM) has 36% inhibition for DAPK3[1].
DAPK-IN-2 (1 μM) has 14% inhibition for DAPK3[1].
| Catalog Number | I041141 |
| CAS Number | 304000-05-3 |
| Synonyms | (4Z)-2-(3,4-dimethoxyphenyl)-4-(pyridin-3-ylmethylidene)-1,3-oxazol-5-one |
| Molecular Formula | C17H14N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H14N2O4/c1-21-14-6-5-12(9-15(14)22-2)16-19-13(17(20)23-16)8-11-4-3-7-18-10-11/h3-10H,1-2H3/b13-8- |
| InChIKey | VQKPPWJEZADXST-JYRVWZFOSA-N |
| SMILES | COC1=C(C=C(C=C1)C2=NC(=CC3=CN=CC=C3)C(=O)O2)OC |
| Reference | [1]. Okamoto M, et al. Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening. Bioorg Med Chem. 2010;18(7):2728-2734. |
